400073-68-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl N-Boc-2-oxopiperidine-3-carboxylate serves as an essential intermediate for the synthesis of a wide range of drugs and bioactive compounds. Its role in the development of new medications is crucial, as it allows for the protection of specific functional groups during the synthesis process, ensuring the successful creation of the desired pharmaceutical products.
Used in Research Laboratories:
In research settings, Methyl N-Boc-2-oxopiperidine-3-carboxylate is employed for the preparation of chemical compounds and the execution of various organic chemistry reactions. Its presence in laboratories facilitates the exploration of new chemical pathways and the discovery of novel compounds with potential applications in medicine, materials science, and other fields.
Used as a Building Block in Organic Synthesis:
Due to its versatile reactivity and compatibility with functional groups, Methyl N-Boc-2-oxopiperidine-3-carboxylate can be used as a building block for the synthesis of other organic molecules. This makes it a valuable component in the creation of complex organic structures, which can be further utilized in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 675-20-7 piperidin-2-one 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 79-22-1 methyl chloroformate 
• 106412-35-5 N-benzyloxycarbonyl-2-piperidone 

Downstream Products

• 1392109-77-1 N-(tert-butoxycarbonyl)-3-[(11-tert-butyldiphenylsilyloxy)undecyl]-3-(methoxycarbonyl)-2-piperidone 
• 1392110-20-1 13-(benzyloxymethyl)-1-azabicyclo[11.3.1]heptadecane 
• 1392109-84-0 3-(benzyloxymethyl)-N-(tert-butoxycarbonyl)-3-piperidineundecanaldehyde 
• 1392110-19-8 13-(benzyloxymethyl)-2-oxo-1-azabicyclo[11.3.1]-heptadecane 
• 1392109-83-9 3-(benzyloxymethyl)-N-(tert-butoxycarbonyl)-3-piperidineundecanoic acid 
• 1392109-81-7 3-(benzyloxymethyl)-N-(tert-butoxycarbonyl)-3-(11-hydroxyundecyl)piperidine 
• 1392109-80-6 N-(tert-butoxycarbonyl)-3-[(11-tert-butyldiphenylsilyloxy)undecyl]-3-(methoxymethyl)piperidine 
• 1392109-79-3 3-(benzyloxymethyl)-N-(tert-butoxycarbonyl)-3-[(11-tertbutyldiphenylsilyloxy)undecyl]piperidine 
• 1392109-78-2 N-(tert-butoxycarbonyl)-3-[(11-tert-butyldiphenylsilyloxy)undecyl]-3-(hydroxymethyl)piperidine 
• 137031-90-4 Methyl 7-<8-methylsulphonyloxy-(Z)-oct-3-enyl>-1-oxo-8-phenylthio-1,2,3,4,4a,5,8,8a-octahydroisoquinoline-8a-carboxylate 

Relevant academic research and scientific papers

Diastereoselective conjugate addition of organocuprates to chiral racemic olefinic amido esters. Formal total synthesis of paroxetine

The diastereoselective conjugate addition of an organocopper reagent to a chiral racemic olefinic amido ester has been used as the key step in a formal total synthesis of paroxetine.

A short formal synthesis of paroxetine. Diastereoselective cuprate addition to a chiral racemic olefinic amido ester

A diastereoselective conjugate addition of an organocopper reagent to a chiral racemic olefinic amido ester has been used as the key step in a formal total synthesis of paroxetine.

A Unified Strategy for the Synthesis of Difluoromethyl- And Vinylfluoride-Containing Scaffolds

Here, we report a general method for the synthesis of quaternary and tertiary difluoromethylated compounds and their vinylfluoride analogues. The strategy, which relies on a two-step sequence featuring a C-selective electrophilic difluoromethylation and either a palladium-catalyzed decarboxylative protonation or a Krapcho decarboxylation, is practical, scalable, and high yielding. Considering the generality of the method and the attractive properties offered by the difluoromethyl group, this approach provides a valuable tool for late-stage functionalization and drug development.

SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

Model studies on the synthesis of madangamine alkaloids. Assembly of the macrocyclic rings

Using simplified model derivatives, the assembly of the macrocyclic rings of madangamines, including the 13- and 14-membered D rings of madangamines C-E, the all-cis-triunsaturated 15-membered D ring of madangamine A, and the (Z,Z)-unsaturated 11-membered E ring common to madangamines A-E, has been studied.

A Diels-Alder Approach to Functionalized cis-Hydroisoquinolines. Attempts to Prepare a Tricyclic Core Unit of Manzamine A

A dihydropyridinone 8 has been synthesized and shown to undergo efficient Lewis-acid mediated Diels-Alder cycloadditions leading to functionalized cis-hydroisoquinoline products such as 11, 13 and 14.Additional manipulations of both the dienophile 8 and a

A DIELS-ALDER APPROACH TO FUNCTIONALISED CIS-HYDROISOQUINOLINES

A new substituted 5,6-dihydro-2(1H)-pyridinone participates in highly efficient Diels-Alder reactions to give functionalised cis-hydroisoquinolines suitable for natural product synthesis.